Physician profile
Emory Wade Walker
NPI 1538182431
$9,071.42
in general payments reported to CMS, 2019-2025
43 companies · $1,050 in 2025
The $1,050 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,139 · 2020: $1,263 · 2021: $1,626 · 2022: $1,243 · 2023: $1,423 · 2024: $1,328 · 2025: $1,050.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,801.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,800.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,485.42 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,046.27 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $959.98 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $569.53 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Sanofi-Aventis U.S. LLC | $538.32 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $500.05 | 2021-2025 | |
| Abbvie INC. | $424.38 | 2020-2025 | Qulipta, Ubrelvy |
| Amgen INC. | $418.98 | 2019-2024 | Repatha, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $417.80 | 2019-2025 | Trintellix |
| Glaxosmithkline, LLC. | $265.64 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Pfizer INC. | $254.59 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $214.87 | 2023-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $186.80 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $129.22 | 2019-2024 | Xifaxan |
| Idorsia Pharmaceuticals US INC | $125.51 | 2022-2024 | Quviviq |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $122.71 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $119.16 | 2022 | |
| Eisai INC. | $116.80 | 2020-2021 | |
| Sanofi Pasteur INC. | $105.70 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $104.50 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $85.76 | 2021 | |
| Exact Sciences Corporation | $85.57 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Mylan Specialty L.P. | $79.52 | 2020-2024 | Yupelri |
| Genentech USA, INC. | $77.32 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $75.71 | 2019-2024 | Capvaxive, Gardasil 9, Vaxneuvance |
| Amarin Pharma, INC. | $65.87 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $61.01 | 2021 | |
| Antares Pharma, INC. | $51.96 | 2020-2021 | |
| Astellas Pharma US INC | $50.29 | 2023-2024 | Veozah, Myrbetriq |
| Dexcom, INC. | $33.27 | 2024-2025 | Dexcom G6 Transmitter |
| Horizon Therapeutics Plc | $32.80 | 2020-2021 | |
| Biogen, INC. | $28.71 | 2025 | Skyclarys |
| Axsome Therapeutics, INC. | $28.67 | 2025 | Auvelity |
| Allergan, INC. | $28.40 | 2020 | |
| Shire North American Group INC | $28.11 | 2019 | |
| C. R. Bard, INC. & Subsidiaries | $26.96 | 2023 | Purewick Female External Catheter |
| Lundbeck LLC | $23.35 | 2024 | Rexulti |
| Abbott Laboratories | $19.30 | 2021 | |
| Arbor Pharmaceuticals, INC. | $18.43 | 2019 | |
| Ironshore Pharmaceuticals INC. | $16.68 | 2019 | |
| Phathom Pharmaceuticals, INC. | $16.37 | 2024 | Voquezna |
| Sunovion Pharmaceuticals INC. | $16.26 | 2019 | |
| Boston Scientific Corporation | $14.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emory Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.